When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KPTI - Karyopharm's selinexor showed positive action in mid-stage lymphoma study
Karyopharm Therapeutics Inc.
Results from a Phase 2 clinical trial, SADAL, evaluating Karyopharm Therapeutics' (NASDAQ:KPTI) Xpovio (selinexor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) were just published online in The Lancet Haematology.
More news on: Karyopharm Therapeutics Inc., Healthcare stocks news,